Hans Bender

Q: What Schools Are Affiliated With Hans Bender

Hans Bender is affiliated with the following schools: Humboldt University of Berlin, University of Freiburg, University of Bonn, Heidelberg University

Hans Bender's AcademicInfluence.com Rankings

Hans Bender

Psychology

#120

World Rank

#208

Historical Rank

psychology Degrees

Download Badge

Psychology

Why Is Hans Bender Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Hans Bender was a German lecturer on the subject of parapsychology, who was also responsible for establishing the parapsychological institute Institut für Grenzgebiete der Psychologie und Psychohygiene in Freiburg. For many years his pipe smoking, contemplative figure was synonymous with German parapsychology. He was an investigator of 'unusual human experience', e.g. poltergeists and clairvoyants. One of his most famous cases was the Rosenheim Poltergeist.

(See a Problem?)

Hans Bender's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Malignant astrocytomas treated with iodine-125 labeled monoclonal antibody 425 against epidermal growth factor receptor: a phase II trial. (1992) (160)
Availability of rhenium-188 from the alumina-based tungsten-188/rhenium-188 generator for preparation of rhenium-188-labeled radiopharmaceuticals for cancer treatment. (1997) (149)
Dose escalation study with rhenium-188 hydroxyethylidene diphosphonate in prostate cancer patients with osseous metastases (2000) (144)
Comparison of 18FDG-PET with 131iodine and 99mTc-sestamibi scintigraphy in differentiated thyroid cancer. (1997) (143)
Redifferentiation therapy-induced radioiodine uptake in thyroid cancer. (1998) (132)
Value of 18fluoro-deoxyglucose positron emission tomography in the staging of recurrent breast carcinoma. (1997) (120)
Detection of somatostatin receptor-positive tumours using the new 99mTc-tricine-HYNIC-d-Phe1-Tyr3-octreotide: first results in patients and comparison with 111In-DTPA-d-Phe1-octreotide (2000) (110)
Fluorine-18 fluorodeoxyglucose positron emission tomography in the follow-up of differentiated thyroid cancer (1996) (106)
"High-dose" radioiodine therapy in advanced differentiated thyroid carcinoma. (1996) (87)
Experimental radiotherapy of receptor‐positive human prostate adenocarcinoma with 188Re‐RC‐160, a directly‐radiolabeled somatostatin analogue (1996) (79)
Immunotherapy of human glioma xenografts with unlabeled, 131I-, or 125I-labeled monoclonal antibody 425 to epidermal growth factor receptor. (1992) (73)
Redifferentiation therapy with retinoic acid in follicular thyroid cancer. (1998) (67)
FDG PET and immunoscintigraphy with 99mTc-labeled antibody fragments for detection of the recurrence of colorectal carcinoma. (2000) (64)
Fluorodeoxyglucose whole-body positron emission tomography in colorectal cancer patients studied in routine daily practice (1997) (63)
Standardized uptake values of fluorine-18 fluorodeoxyglucose: the value of different normalization orocedures (1996) (54)
Epidermal growth factor receptor 425 monoclonal antibodies radiolabeled with iodine-125 in the adjuvant treatment of high-grade astrocytomas. (1995) (53)
188Re- and 99mTc-MAG3 as prosthetic groups for labeling amines and peptides: approaches with pre- and postconjugate labeling. (1998) (47)
Possible role of FDG-PET in the early prediction of therapy outcome in liver metastases of colorectal cancer. (1999) (47)
Scintimammography with technetium-99m methoxyisobutylisonitrile: comparison with mammography and magnetic resonance imaging (1996) (46)
Possible role of FDG-PET in the evaluation of urologic malignancies. (1997) (44)
Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and technetium-99m methoxyisobutylisonitrile scintimammography in the detection of breast tumours (1997) (41)
Intraarterial HCC therapy with I-131-Lipiodol. (2000) (40)
Indium‐111‐labeled anti‐egfr‐425 scintigraphy in the detection of malignant gliomas (1994) (33)
Clinical PET in oncology. (2000) (25)
18F-fluorodeoxyglucose-PET and99mTc-bicisate-SPECT in Creutzfeldt-Jakob disease (1996) (25)
Pain palliation with rhenium-186 HEDP in breast cancer patients with disseminated bone metastases. (1999) (24)
Pre-clinical experience with Re-188-RC-160, a radiolabeled somatostatin analog for use in peptide-targeted radiotherapy. (1997) (24)
Recombinant human thyrotropin in thyroid cancer and hypopituitarism due to sella metastasis. (1999) (19)
The use of epidermal growth factor receptor-425 monoclonal antibodies radiolabeled with iodine-125 in the adjuvant treatment of patients with high grade gliomas of the brain. (1996) (18)
Effects of diagnostic application of monoclonal antibody on survival in melanoma patients. (1997) (17)
Localization of Small‐cell Lung Cancer Xenografts with Iodine‐125‐, Indium‐111‐, and Rhenium‐188‐Somatostatin Analogs (1996) (14)
Fdg-pet in clinical oncology: review and evaluation of results of a private clinical pet center (1998) (13)
Utilization of 125I monoclonal antibody in the management of primary glioblastoma multiforme (1995) (13)
Indium-111-labeled anti-EGFr-425 scintigraphy in the detection of malignant gliomas. (1992) (12)
Targeting peptides for pleural cavity tumor radiotherapy: specificity and dosimetry of Re-188-RC-160. (1997) (11)
Clinical aspects of local and regional tumor therapy with 188Re-RC-160. (1997) (11)
[Monoclonal anti-idiotype antibodies in immunotherapy of ovarian carcinoma (MAb ACA125) and breast carcinoma (MAb ACA14C5)]. (1999) (11)
Biodistribution of 125I-MAb 425 in a human glioma xenograft model: effect of chloroquine. (1997) (10)
In vitro evaluation of iodine-125-labeled monoclonal antibody (MAb 425) in human high-grade glioma cells. (1996) (10)
Enhancement of monoclonal antibody efficacy: the effect of external beam radiation. (1995) (9)
Effects of induction of multi-drug resistance on accumulation of 99mTc-sestamibi in vitro. (1997) (9)
External beam radiation enhances antibody mediated radiocytotoxicity in human glioma cells in vitro. (1997) (8)
Localization of colorectal carcinoma by rhenium-188-labeled B72.3 antibody in xenografted mice (1998) (8)
40. 188Re: Cost-effective therapeutic applications of a readily available generator-derived radioisotope (1996) (7)
I-131-Lipiodol therapy in liver neoplasms. (1999) (7)
Myocardial Uptake of Technetium-99m-Furifosmin (Q12) Versus Technetiiim-99m-Sestamibi (MIBI) (1999) (6)
Atlas of Clinical PET in Oncology (2000) (6)
Ascorbic Acid Stabilization of Re-188- and I-131-Radiolabeled Peptides for Radiotherapy (1997) (5)
Clinical Indications for the Use of Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography in Thyroid Cancer. (1998) (4)
Atlas of clinical PET in oncology : PET versus CT and MRI (2000) (4)
[Pain therapy with rhenium-186 HEDP in multiple bone metastases]. (1996) (4)
[PET scan in general practice for diagnosis of breast carcinoma]. (1997) (3)
Radioimmunoimaging of Head and Neck Cancer (1993) (3)
99mTc-MIBI-SPECT-studies in the evaluation of brain tumors (1994) (2)
[Diagnostic value of pentavalent 99mTc-dimercaptosuccinicacid ([V]-DMSA) in head and neck tumors]. (2000) (2)
Therapy with Rhenium-186 HEDP in Painful Bone Metastases (1996) (2)
Pre-injection of unlabeled monoclonal antibody improves the uptake of labeled antibody in glioma patients in vivo (1994) (1)
[Toxicity and radiation dosage of 2-(18F)-2-desoxy-D-glucose in positron emission tomography]. (1998) (1)
Clinical-scale tungsten-188/rhenium-188 generators routinely provide > 18 GBq (500 mCi) ml 1specific volume solutions of carrier-free rhenium-188: Recent generator improvements and first clinical applications (1997) (0)
Clinical Application of 18FDG-PET in the Assessment of Head and Neck Tumors (1999) (0)
Immunoradiotherapy with 125-I labeled monoclonal antibodies in advanced neoplastic diseases (1993) (0)
Gynecological Tumors (Except Breast Cancer) (2000) (0)
Comparison of [ lSF ] FDG-PET and L-31123 I ]-iodo-ct-methyl tyrosine ( I-123 IMT )-SPECT in primary lung cancer (0)
Clinical Relevance of Radio-immunoimaging in Malignant Diseases (1993) (0)
Interim report on intrathoracic radiotherapy of human small-cell lung carcinoma in nude mice with Re-188-RC-160, a radiolabeled somatostatin analogue (1995) (0)
Direct radiolabeling of the somatostatin analogs RC-160 and octreotide with {sup 99m}Tc and {sup 188}Re: Initial results with stannous reductions (1994) (0)
FC118 Positron emission tomographie in melanoma staging (1997) (0)
[Evaluation of 99mTc(V)-DMSA imaging in patients with pharyngolaryngeal carcinoma]. (1999) (0)
Utilization of the radiolabeled mab 425/emd 55 900 in the management of high grade gliomas (1992) (0)
Radiotracer binding to brain microsomes determined by thin-layer chromatography. (1996) (0)
Contents, Vol. 16, 1993 (1983) (0)
FDG-PET, I-131 and MIBI Scintigraphy in the Follow-Up of Differentiated Thyroid Cancer (1997) (0)
Potential Role of Whole-Body 18FDG-PET in the Routine Staging of Malignant Melanoma (1999) (0)

This paper list is powered by the following services:

Other Resources About Hans Bender

en.wikipedia.org

What Schools Are Affiliated With Hans Bender?

Hans Bender is affiliated with the following schools: